Ann: Results of LCT Parkinsons trial require further analysis, page-31

Correction to my earlier post: the best group by far was the group with the intermediate doseage, the brown line on the graph.

Before jumping to conclusions, a possibility exists that one or two patients responded far better than the others to generate this result. It might also have been the case with the phase 1 patients that one of them did much better than the others. So it could be that response has been more influenced by the patient disease characteristics more than the dose given.

Which is why I said earlier that patient selection is often the reason for trial failure.

Anyway, they will have the 52 week data for the first cohort already, and for the second cohort just before Christmas. That may provide some further insight. Presumably since they didn't mention the 52 week data they have, it didn't reveal anything new.